Biomedicine for the future.
We aim to become a global reference in the valorization of biomedical projects in the field of the Neurosciences, supporting and promoting the transfer of technology between academia and the private sector, with special emphasis on Multiple Sclerosis. Our efforts will mainly be directed towards obtaining new innovative drugs and biomarkers, and introducing them onto the market to create a positive impact on society.
Bionure aims to help society through Biomedicine.
By developing innovative, more effective and safer treatments, Bionure’s mission is to improve the control of Multiple Sclerosis, as well as that of other neurological and ophthalmological diseases.
We aim to identify and incorporate different research projects with a strong commercial potential from the academic sphere (universities, hospitals, research centres) that potentially cover unsatisfied medical needs, initially focusing on the development of neuroprotective therapies for the early stages of Multiple Sclerosis (discovery). Moreover, we also plan to identify biomarkers that can be developed to diagnose the disease, and to be used as prognostic and predictive tests.
We will pursue the valorization of these projects, developing them to more advanced stages (e.g., completion of preclinical and initial clinical stages).
Bionure seeks to develop neuroprotective therapies for Multiple Sclerosis and other brain diseases based on the most recent discoveries in neuroscience and applied immunology. In order to aid such findings along the pathway to innovation, we will apply a systems biology approach whereby medical knowledge will be combined with the power of computers to better predict the efficacy of the therapies.
Technology
In order to benefit adequately from cutting edge discoveries, we maintain a network of collaborators from the most important universities and research centres from around the world. In particular, we maintain a close collaboration with the research groups from which the project has been spawned (The Neuroimmunology group of Hospital Clinic-IDIBAPS and combinatory chemistry unit at the CSIC).
The strategy at Bionure is to obtain the knowledge required to develop neuroprotective therapies by establishing partnerships with academic centres and clinical research organizations in Europe and the U.S.A.
Bionure is open to collaborate with academic groups and other biotech companies in EU or NIH research applications. Bionure is also willing to contribute its technology and know-how of preclinical and clinical development to other neuroprotective therapies.
Fundación GAEM and Bionure organize the webinar ‘New neuroprotectant treatments and combined therapies’
Bionure
Bionure lanza una campaña de ‘crowdfunding’ para poner en marcha los estudios de Fase 2 de su neuroprotector BN201
Bionure
Bionure, biotecnológica especializada en neuroprotección, ha completado con éxito el estudio clínico de Fase 1 de su candidato BN201
Bionure
Alta Life Sciences leads a Series A round of 4 million euros in Bionure
Bionure
Bionure lanza una campaña de crowdfunding en Capital Cell para captar 1,2 millones de euros
Bionure
